BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/6/2018 1:33:44 AM | Browse: 1057 | Download: 1183
 |
Received |
|
2018-05-22 11:05 |
|
Peer-Review Started |
|
2018-05-23 07:34 |
|
To Make the First Decision |
|
2018-06-06 02:06 |
|
Return for Revision |
|
2018-06-11 07:53 |
|
Revised |
|
2018-06-22 10:08 |
|
Second Decision |
|
2018-06-27 09:45 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-06-27 17:23 |
|
Articles in Press |
|
2018-06-27 17:23 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-08-31 09:12 |
|
Publish the Manuscript Online |
|
2018-09-06 01:33 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Kai Wang, Graham S Baldwin, Mehrdad Nikfarjam and Hong He |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hong He, MD, PhD, Senior Research Fellow, Department of Surgery, University of Melbourne, Austin Health, Studley Rd., Heidelberg, Victoria, Melbourne 3084, Australia. hong.he@unimelb.edu.au |
| Key Words |
Pancreatic cancer; Kras; p21-activated kinases; Cell signalling; Chemo-resistance; Immune response; Tumour microenvironment |
| Core Tip |
Pancreatic cancer is still one of the most lethal malignancies, with a five-year survival of less than 8%. The dismal prognosis is largely the result of reprogramming of the tumour microenvironment, which leads to chemo-resistance and high aggressiveness. So far, combination chemotherapies can only marginally improve patients’ survival, but with high toxicity. Therefore, alternative treatment targeting protein kinase signalling has been proposed. As downstream effectors of Kras signalling, p21-activated kinases (PAKs) are positioned at the nexus of multiple oncogenic signalling pathways. Here, the importance of PAKs as therapeutic targets in Kras signalling is discussed, and their essential role in tumour biology and immune modulation within the tumour microenvironment is highlighted. |
| Publish Date |
2018-09-06 01:33 |
| Citation |
Wang K, Baldwin GS, Nikfarjam M, He H. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. World J Gastroenterol 2018; 24(33): 3709-3723 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i33/3709.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i33.3709 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
